Chronic Progressive Numbness and Weakness: Hereditary versus Acquired
A 38-year-old man presents with 8 years of slowly progressive distal numbness and weakness, now with frequent trips and difficulty with fine hand tasks. He has no pain. Exam: distal-predominant weakness (ankle dorsiflexion 4/5, finger abduction 4/5), absent ankle reflexes, reduced vibration and pinprick distally, and mild pes cavus with hammer toes. His mother has 'bad feet' and wore braces as a child. CK is normal. He has no diabetes, no alcohol use, and no toxin exposure. He asks whether this could be hereditary and whether he needs treatment.
1. What clinical features favor a hereditary neuropathy over CIDP, and what is the role of genetic testing versus electrodiagnostics?
Read the worked answer
Several features favor a hereditary neuropathy (e.g., Charcot-Marie-Tooth) over CIDP:
- Very slow, symmetric, distal-predominant progression over years without pain or relapses.
- Family history suggestive of a hereditary neuropathy (mother with foot problems and bracing).
- Skeletal features: pes cavus and hammer toes, which reflect long-standing imbalance and support a chronic, likely hereditary process.
- Absent ankle reflexes with distal sensory loss and no proximal or cranial involvement.
- Normal CK and no systemic or toxic cause.
CIDP would more typically show a relapsing or progressive course over months, often with proximal weakness, areflexia beyond the distal distribution, sensory ataxia, and responsiveness to immunotherapy; family history and skeletal deformities would be atypical.
Role of testing:
- EMG/NCS is the key first test: it distinguishes demyelinating from axonal physiology and can show uniform, symmetric slowing (favoring hereditary) versus non-uniform conduction block/dispersion (favoring acquired CIDP).
- Genetic testing (e.g., PMP22 duplication for CMT1A, or panels for other CMT subtypes) confirms the diagnosis and informs counseling, but electrodiagnostics guides which gene to prioritize.
- A trial of immunotherapy is not appropriate without evidence of an acquired, immune-mediated process; treating a hereditary neuropathy with IVIG or steroids exposes the patient to risk without benefit.
2. If electrodiagnostics show uniform demyelination without conduction block, how should the patient be counseled and what should be avoided?
Read the worked answer
Uniform, symmetric demyelination without conduction block or temporal dispersion supports a hereditary demyelinating neuropathy, most commonly CMT1 (often CMT1A from a PMP22 duplication).
Counseling:
- Explain the chronic, slowly progressive nature and the generally favorable long-term outlook for many patients, while acknowledging variable severity.
- Discuss inheritance pattern (autosomal dominant for CMT1A) and offer genetic counseling and testing for family members as appropriate.
- Emphasize supportive management: ankle-foot orthoses for foot drop, physical and occupational therapy, fall prevention, foot care, and monitoring for secondary complications.
- Address modifiable factors: avoid neurotoxic medications where possible, maintain good nutrition, and manage any emerging comorbidities.
What to avoid:
- Do not start immunotherapy (IVIG, plasma exchange, corticosteroids) for a hereditary neuropathy; there is no evidence of benefit and there are real risks.
- Avoid neurotoxic drugs (e.g., certain chemotherapeutics, excessive alcohol, and other neurotoxins) that could accelerate progression.
- Avoid attributing new symptoms to the hereditary neuropathy without evaluation; a superimposed treatable cause (e.g., compression neuropathy, vitamin deficiency, diabetes) should be considered if the course changes.
The judgment call: recognizing the hereditary pattern prevents unnecessary and potentially harmful immunotherapy, and shifts care to supportive and genetic management.